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Objectives: Existing practice guidelines for osteoarthritis (OA) analyze the evidence behind each
proposed treatment but do not prioritize the interventions in a given sequence. The objective was to
develop a treatment algorithm recommendation that is easier to interpret for the prescribing physician
based on the available evidence and that is applicable in Europe and internationally. The knee was used
as the model OA joint.
Methods: ESCEO assembled a task force of 13 international experts (rheumatologists, clinical epidemi-
ologists, and clinical scientists). Existing guidelines were reviewed; all interventions listed and recent
evidence were retrieved using established databases. A ﬁrst schematic ﬂow chart with treatment
prioritization was discussed in a 1-day meeting and shaped to the treatment algorithm. Fine-tuning
occurred by electronic communication and three consultation rounds until consensus.
Results: Basic principles consist of the need for a combined pharmacological and non-pharmacological
treatment with a core set of initial measures, including information access/education, weight loss if
overweight, and an appropriate exercise program. Four multimodal steps are then established. Step
1 consists of background therapy, either non-pharmacological (referral to a physical therapist for re-
alignment treatment if needed and sequential introduction of further physical interventions initially and
at any time thereafter) or pharmacological. The latter consists of chronic Symptomatic Slow-Acting Drugs
for OA (e.g., prescription glucosamine sulfate and/or chondroitin sulfate) with paracetamol at-need;
topical NSAIDs are added in the still symptomatic patient. Step 2 consists of the advanced pharmaco-
logical management in the persistent symptomatic patient and is centered on the use of oral COX-2r HS Journals, Inc. This is an open access article under the CC BY-NC-ND license
ère).
O. Bruyère et al. / Seminars in Arthritis and Rheumatism 44 (2014) 253–263254selective or non-selective NSAIDs, chosen based on concomitant risk factors, with intra-articular
corticosteroids or hyaluronate for further symptom relief if insufﬁcient. In Step 3, the last pharmaco-
logical attempts before surgery are represented by weak opioids and other central analgesics. Finally,
Step 4 consists of end-stage disease management and surgery, with classical opioids as a difﬁcult-to-
manage alternative when surgery is contraindicated.
Conclusions: The proposed treatment algorithm may represent a new framework for the development of
future guidelines for the management of OA, more easily accessible to physicians.
& 2014 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Osteoarthritis (OA) is the most common form of arthritis and a
major cause of disability [1]. The most prevalent OA localization is
the knee joint, and symptomatic knee OA affects 24% of the general
population [2]; thus, it represents the model for the development
of treatment guidelines. Recommendations for the management of
knee OA have been issued by national, continental, or global
scientiﬁc authorities, including, among others, the European
League Against Rheumatism (EULAR) [3]; the American College
of Rheumatology (ACR) [4]; and the Osteoarthritis Research
Society International (OARSI) [5–8]. The UK National Institute for
Health and Clinical Excellence (NICE) has also issued a guideline
document for the management of OA in adults [9,10].
The European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO) has promoted the crea-
tion of different expert working groups in the ﬁeld of OA to
analyze and generate consensus documents on disease manage-
ment [11,12]. With respect to treatment guidelines, ESCEO felt the
need to ﬁnd a common denominator to the published guidelines
and recommendation documents from different sources and gen-
erate a treatment algorithm applicable throughout Europe and
elsewhere. Most of the existing practice guidelines analyze the
evidence behind each proposed treatment but do not (often
deliberately) prioritize the interventions because few clinical trials
have been designed to study the effect of a given treatment in
patients in whom initial therapies have failed and/or when and
how new treatments should be introduced. Therefore, treatment
remains based on the individualized assessment of the patient,
taking into account patients' needs and preferences, or the sub-
jective interpretation of the evidence by the physician. On the
other hand, careful analysis of the evidence actually allows one to
prioritize interventions and guide physicians into progressive and
logical steps. In addition, it was necessary to synthesize the
recommendations for the European situation, adapting global
guidelines [6–8] to it or using what is applicable from other
continental guidelines [4] and broadening the perspective of some
national guidelines [9,10], providing an initial update of current
European guidelines [3], that can be used virtually universally.
Finally, the present effort may represent a new framework for the
development of recommendations for the treatment of OA that is
more practical and intuitive for practicing physicians than a mere
exposition of the available and often contradicting evidence.Methods
ESCEO gathered an international task force of 13 members,
consisting of 11 rheumatologists (8 from Europe, 2 from USA, and
1 from Canada), 1 clinical epidemiologist, and 1 clinical scientist,
all of whom are experienced in the performance, analysis, and
interpretation of the clinical trial evidence related to OA.
One member of the task force (O.B.) was entrusted with the
task to collect the principal guidelines considered, including themost recent drafts released for consultation [3,4,6–10], and circu-
late them to the task force. Afterwards, an initial list of all
interventions considered in the different documents was com-
piled, preparing a ﬁrst and very schematic ﬂow chart for possible
prioritization of the different interventions, to the extent possible
based on the information within the documents. For each inter-
vention, a complete literature search was performed to identify
new or additional randomized controlled trials and systematic
reviews/meta-analyses, if any, not used in the existing guidelines.
The MEDLINE (PubMed) database was searched using each inter-
vention as a search term together with “osteoarthritis,” limiting
results to “ humans,” “randomized controlled trial,” “meta-analy-
sis,” “review” and “systematic review,” and “guideline.” A similar
search was adapted for the Embase database and each interven-
tion was also searched in the Cochrane Central Register of Con-
trolled Trials, the Cochrane Database of Systematic Reviews, and
the Centre for Reviews and Dissemination of the University of
York. The reference list of relevant retrieved articles was hand-
searched for additional resources, while members of the task force
were interrogated for their knowledge on articles or congress
abstracts in press. A free web search was also performed and
considered. Searches were performed from the year 2000 and
updated until February 2014, with the additional evidence con-
stantly provided to the task force members for selection of the best
evidence according to the panel.
Initial material was presented to the task force, together
with the ﬁrst schematic draft ﬂow chart, in a 1-day meeting
at the end of September 2013. During a detailed discussion, the
initial ﬂow chart was shaped to the treatment algorithm. Each step
and intervention within the steps were discussed and amended
until consensus agreement was achieved within the task force.
A ﬁrst draft of the ﬁnal algorithm and the supporting evidence
was then prepared (O.B.); three rounds of consultation occurred
by electronic communication between December 2013 and
February 2014 on the draft manuscript: all corrections and
suggestions by each member were shared with the rest of the
task force and included till ﬁnal consensus with the third
consultation round.
ESCEO is a not-for-proﬁt organization dedicated to providing
practitioners with the latest clinical evidence in the ﬁeld of bone,
joint, and muscle disorders: the development of practice recom-
mendations is within the institutional scope of the organization to
allow specialist and non-specialist practitioners to organize
their daily clinical activity in an evidence-based medicine per-
spective, with a cost-conscious perception. ESCEO receives Unre-
stricted Educational Grants from several pharmaceutical
companies that do not inﬂuence the institutional activities of the
organization. In particular, the present recommendations were
developed independently of any of the funding sources that had no
role in the decision to prepare this document and its implementa-
tion, revisions, and approval for publication. In addition, each
member of the task force individually agreed to declare their
potential conﬂict of interest, if any, in the process of article
submission.
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Basic principles and core set for a treatment algorithm in knee OA
Appropriate diagnosis of knee OA is an essential pre-requisite
to treatment; in this respect, EULAR recently published updated
recommendations [13].
Virtually all existing practice guidelines agree that combination
of treatment modalities, including non-pharmacological and phar-
macological intervention, is strongly recommended. It was the
ﬁrm opinion of the task force that this basic principle is valid and
makes the effort to develop a treatment algorithm an absolute
priority in order to prevent physicians from being confused as to
how treatments should be prioritized and possibly added on for
combination therapy.
The core set proposed by NICE [9] was adopted and expanded by
the task force to represent the initial measures and interventions
that every patient with knee OA should undergo. In particular,(1) Information access and education consists in providing to the
patient the necessary knowledge about the nature of
the disease and the objectives of treatment. If necessary, the
physician should prompt changes in the patient's lifestyle
toward behaviors that may have a beneﬁcial impact on joint
protection or at least not worsen the progression of the disease
or of its symptoms. It is recognized that these measures have
minimal effect on OA symptoms, but they are essential for
treatment adherence. EULAR has recently published compre-
hensive recommendations for the non-pharmacological man-
agement of hip and knee osteoarthritis that provided extensive
guidance on the principles of information and education, as
well as of lifestyle changes [14].(2) Weight loss if overweight. Analysis of the available evidence
indicates that at least 5% weight loss within 6 months induces
a small but well-substantiated symptomatic beneﬁt, more evi-
dent on physical function than on pain, where the effect is less
predictable [15]. The task force strongly felt that a threshold
should be indicated and, based on previous evidence [15] and a
recent high-quality trial [16], weight loss should be targeted to at
least 10% to achieve signiﬁcant symptom beneﬁt. A similar degree
of weight loss has also been indicated to improve the quality and
thickness of medial femoral compartment cartilage [17].(3) Exercise program. Education should include information about
exercise and physical activity [14] since exercise produces
beneﬁt on both pain and function in patients with knee
osteoarthritis by different delivery modes (individual, group-
based, or home programs) [18]. Although the optimal exercise
dosing and rate of progression in its application remains
unclear, expert opinion suggests that the intensity and/or
duration of exercise should be increased over time [14]. There
is good evidence that water-based exercise is effective on both
pain and function [19]. However, speciﬁc quadriceps strength-
ening exercises or strength training for the lower limb,
together with aerobic training such as walking, remain the
best documented exercise approaches [18]: experts suggest
that mixed programs (to include muscle strengthening, aero-
bic capacity, and ﬂexibility/range of motion) should be recom-
mended [14] as long as minimal intensity requirements are
met [18]. Recent evidence suggests that tai chi is also effective
in relieving symptoms [20].OA treatment algorithm: Beyond the core set
It is a common clinical experience that core therapies are
usually insufﬁcient to fully control symptoms after diagnosis hasbeen made and with disease progression. In agreement with the
basic principle of treatment recommendation, which requires
combination of treatment modalities, parallel addition of sequen-
tial non-pharmacological and pharmacological therapies should be
established. The consequent treatment algorithm that was derived
from the present effort is depicted in the Figure and can be
described as follows.
Step 1: Background treatment
During Step 1, which follows the core set, further background
physical remedies should be established as needed. In parallel, and
if the patient is still symptomatic, background pharmacological
therapy should be started and progressively moved toward com-
bination treatment as soon as the clinical response is not
satisfactory.
Step 1-a: Non-pharmacological background treatment. During Step
1, the patient should be referred to a physical therapist for
assessment to determine whether physical treatments should be
introduced. In particular, the physical therapist should ﬁrst
evaluate whether correction for malalignment is necessary.
Moreover, he/she should also assess, during Step 1 and
throughout steps thereafter at any time, whether other physical
measures may be useful for additional symptom relief in parallel to
the pharmacological interventions established by the physician.
Varus or valgus malalignment is a risk factor for knee OA and its
progression. Therefore, there is a theoretical rationale for using
biomechanical interventions such as braces or insoles in patients
with unicompartmental tibiofemoral OA to reduce malalignment,
to reduce the consequent articular stress, and thus to improve pain
and function, or even retard disease progression. Despite signiﬁ-
cant heterogeneity and poor trial quality, there is reasonable
evidence to suggest that knee braces actually improve biomechan-
ical imbalance [21] and may improve knee OA symptoms [22]. The
same may apply with multi-modal re-alignment treatment that
includes braces, foot orthoses, and appropriate footwear [23].
Among foot orthoses, there are many studies on laterally wedged
insoles in medial compartment knee OA aimed to increase foot
pronation, thereby reducing medial compartment loading. Their
biomechanical effects are more inconsistent [21] and the clinical
efﬁcacy is controversial; in particular, a recent high-quality meta-
analysis found a signiﬁcant effect on pain in all randomized
controlled studies combined, but no effect when the more reliable
higher quality trials were considered [24]. There are fewer studies
on laterally wedged insoles with subtalar strapping and on
medially wedged insoles for unicompartmental lateral OA,
although they tend to show efﬁcacy [22,24]. There is insufﬁcient
evidence to determine whether braces or insoles affect the pro-
gression of knee OA. EULAR did not recommend the use of insoles
among non-pharmacological treatments for knee OA, also in view
of an increased risk of adverse effects [14]. On the other hand,
appropriate footwear (including shock-absorbing soles, foot arches
support, and control for foot pronation if necessary, while avoiding
raised heels) should be recommended [14].
Ideal patients for bracing are younger individuals, more physi-
cally active, not severely obese, with unicompartmental sympto-
matic tibiofemoral OA and malalignment that is reducible by
valgus or varus stress maneuvers on physical examination. For
laterally wedged insoles, patients should also probably have early
and mild disease.
Among additional physical remedies, access to walking aids is
an important help in providing security to patients: although
appropriate clinical studies are scarce, a recent randomized trial
conﬁrmed that use of a cane improves symptoms in knee OA [25].
Referral to a physical therapist may also include assessment for the
use of thermal therapies, such as ultrasound, for which there is
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Fig. Knee osteoarthritis treatment algorithm. COX-2, cyclooxygenase-2; CV, cardiovascular; GI, gastrointestinal; NSAIDs, non-steroidal anti-inﬂammatory drugs; PPI, proton
pump inhibitor; SYSADOA, Symptomatic Slow Acting Drugs in Osteoarthritis.
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Indeed, more recent randomized trials failed to show additional
improvement of ultrasound over a sham procedure [27], or for
manual therapy in combination with exercise, or patellar tapingwhere needed. Balneotherapy and, especially, acupuncture ranked
high in a recent network meta-analysis of all physical treatments
for knee OA [28]. On the other hand, other studies suggest that the
beneﬁt of acupuncture is small, especially compared with sham
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effect [30]. Finally, Transcutaneous Electric Nerve Stimulation
(TENS) is also a possible physical intervention; the evidence is
scarce, especially because of the availability (as it often happens
for physical remedies) of mainly small and low-quality studies
[31]. However, a recent larger randomized trial suggested that
TENS may reduce the need for analgesic medications [32]. Inter-
estingly, the recent ACR guidelines [4] suggested an approach that
would advise reserving acupuncture and TENS as a non-
pharmacological alternative to surgery when this is contraindi-
cated or the patient is unwilling to undergo surgery. There are no
speciﬁc studies in this respect and thus it is correct that both
acupuncture and TENS are listed here and considered throughout
the algorithm ﬂow including, but not necessarily, as an alternative
to surgery.
Step 1-b: Pharmacological background treatment. The aim of Step
1 pharmacological treatment is to establish a ﬁrst chronic therapy
that may improve or control symptoms or at least provide rescue
analgesia.
Paracetamol at doses no greater than 3 g/day on a regular basis
is recommended as an initial pharmacological approach in most
clinical guidelines, despite its minimal effects on symptoms but in
the presumption of acceptable safety and affordable price. How-
ever, a recent meta-analysis [33] outlined that the vast majority of
clinical trials (of either immediate release or extended release
formulations) were performed over durations of less than
6 months, thus questioning paracetamol chronic treatment role;
indeed, the only placebo-controlled study of 6-month duration
found a signiﬁcant effect on function but not on pain [34]. This
meta-analysis also conﬁrmed the small effect size, less than 0.20,
detected in a previous OARSI guideline update [7] and conﬁrmed
in large trials or those analyzed by intention-to-treat [33]. In
addition, there is accumulating evidence for an increased risk of
gastrointestinal adverse events with paracetamol use, with sig-
niﬁcant elevation in liver enzymes [7]. Indeed, paracetamol is the
most frequent cause of drug-induced liver injury in the United
States and over half of such cases are due to unintentional
ingestion.
A safer and more sensible approach would be to use as a
background therapy, chronic Symptomatic Slow-Acting Drugs for
Osteoarthritis (SYSADOAs), with as needed paracetamol for short-
term, rescue analgesia. Among SYSADOAs, prescription glucos-
amine sulfate should be differentiated from other glucosamine
preparations. The latest update of a speciﬁc Cochrane Review [35]
clearly showed that while the overall pain beneﬁt of all glucos-
amine formulations together is jeopardized by high heterogene-
ity, subgroup analysis of non-prescription glucosamine high-
quality trials showed no beneﬁt versus placebo [35]. Conversely,
high-quality trials of the patented prescription formulation
approved in Europe and elsewhere (crystalline glucosamine
sulfate) showed that it was superior to placebo in the treatment
of pain and functional impairment [35]: all three pivotal trials
[34,36,37] are long-term studies of 6 months to 3 years treatment
in patients with mild-to-moderate pain and the calculated global
effect size, without heterogeneity, is 0.27 (95% CI: 0.12–0.43) on
pain and 0.33 (95% CI: 0.17–0.48) on function [38], i.e., in about
the same range of short-term trials of oral non-steroidal anti-
inﬂammatory drugs (NSAIDs) [39]. A recent network meta-
analysis, again mixing all formulations [40], was criticized for
severe methodological ﬂaws [41] and the journal editor withdrew
the article's negative conclusions [42]. The ACR guidelines did not
recommend glucosamine because they noted that glucosamine is
not a prescription drug in the USA, but only dietary supplements
exist whose quality has not been evaluated by the FDA [4]. In
addition, such dietary supplements often contain glucosaminehydrochloride and a large, NIH-sponsored trial showed no beneﬁt
of this preparation [43], similar to other studies of glucosamine
hydrochloride [7,9]; indeed, these formulations have a different
pharmacokinetic proﬁle than prescription glucosamine sulfate
1500 mg once daily approved in Europe [44], and appropriate
bioequivalence studies should be conducted before recommend-
ing glucosamine generic or OTC products [35]. Long-term pre-
scription glucosamine sulfate may delay joint structure changes
[36,37], suggesting potential beneﬁt beyond symptom control
when used early in the management of knee OA as recommended
here.
Chondroitin sulfate may offer similar beneﬁts on joint structure
changes in patients with mild-to-moderate disease [45–47] using
prescription chondroitin 4&6 sulfate. It should, however, be
acknowledged that joint structure modiﬁcation is not an approved
indication for either prescription chondroitin or glucosamine
sulfate but a potential beneﬁt when they are used for long-term
symptom control. In this respect, the data on chondroitin sulfate
have been reported as conﬂicting [48], but the effect size on pain
in meta-analyses ranges from 0.13 (0.00–0.27) to 0.75 (0.50–0.99)
[8]. On the other hand, full data of one pivotal trial on chondroitin
4&6 sulfate have been published more recently and show chon-
droitin sulfate to reduce joint structural changes with a sympto-
matic effect that could be clinically relevant [46], as conﬁrmed in
another recent study [49]. The prescription drug used in this study
[46] should be distinguished from low-quality OTC products
available outside of Europe. As for glucosamine sulfate, the
negative conclusions of a recent network meta-analysis [40] were
withdrawn by the editor [42].
Beside their efﬁcacy record, both glucosamine sulfate and
chondroitin are safe medications, with no difference in adverse
effects compared with placebo [35,46], which would also
strengthen their role as chronic background treatments. Glucos-
amine and chondroitin sulfate are often used in combination as
dietary supplements. Unfortunately, there are no published
trials of the two pharmaceutical-grade prescription prepara-
tions combined. On the other hand, the previously mentioned
NIH-sponsored trial [43], while ﬁnding no overall beneﬁt,
described a signiﬁcant symptomatic effect in an exploratory
analysis of patients with moderate-to-severe pain receiving a
glucosamine hydrochloride and chondroitin sulfate combination
[43]. Indeed, a similar combination has been shown to have
comparable efﬁcacy to celecoxib after 6 months in knee OA
patients with moderate-to-severe pain (Hochberg et al., abstract
presented at OARSI 2014). More interestingly, and following
preliminary data from the Osteoarthritis Initiative database [50],
a recently published trial from Australia found signiﬁcant and
clinically relevant joint structure modiﬁcation after 2 years with
a non-prescription or pharmaceutical-grade chondroitin/glucos-
amine sulfate combination, with apparently no effects on
symptoms given the very mild and placebo responsive popula-
tion studied [51].
The evidence for efﬁcacy of other SYSADOAs, such as avocado
soybean unsaponiﬁables (ASU) and diacerein, is more scarce
[52,53]. With respect to diacerein, the European Medicines Agency
(EMA) recently informed that despite the most recent meta-
analysis showing some degree of efﬁcacy without heterogeneity,
safety issues may outline a negative beneﬁt/risk ratio and a re-
assessment was recommended [54]. Furthermore, newer drugs are
gaining credit for their possible role as disease-modifying agents in
OA, e.g., strontium ranelate (SR), a chemical entity currently
marketed for the treatment of postmenopausal osteoporosis and
osteoporosis in males. SR exhibited effects on subchondral bone
and cartilage, which may be suggestive of a beneﬁcial effect on OA
progression. A recent high-quality 3-year placebo-controlled trial
showed that SR decreases radiological progression of knee OA,
O. Bruyère et al. / Seminars in Arthritis and Rheumatism 44 (2014) 253–263258together with improving symptoms [55]. The drug was well
tolerated in this trial, but the EMA recently restricted the use of
SR to the treatment of severe osteoporosis due to a possible
increase in cardiovascular risk [56]; therefore, the role of the drug
in the management of OA will need further reassessment.
If the patient is still symptomatic after establishing appropriate
background pharmacological therapy with SYSADOAs and rescue
analgesia with paracetamol is insufﬁcient, topical NSAIDs may be
added to the pharmacological background and in parallel with
non-pharmacological treatment. The efﬁcacy of topical NSAIDs
was established in several randomized trials that were systemati-
cally reviewed in 2004 [57]; the evidence shows a moderate effect
size in the relief of OA pain [9] with high heterogeneity possibly
due to differences between topical products. Recent randomized
trials conﬁrmed that there is no signiﬁcant difference between
topical NSAIDs and their oral counterpart, with topical formula-
tions showing better gastrointestinal safety but more local cuta-
neous reactions, including in large studies [58,59] and as discussed
in a comprehensive systematic review [60]. However, most of the
studies were for r12 weeks, which would conﬁrm topical NSAIDs'
role as cyclic add-on analgesics if the background treatment leaves
the patient symptomatic. Only one study performed in general
practice [61] conﬁrmed similar ﬁndings over 1 year, but the study
did not meet all quality standards of a rigorous randomized
controlled trial and was not blinded [61].
While topical rubefacients containing salicylates did not show
efﬁcacy compared with placebo in OA, with increased risk of local
adverse reactions [62], there is no particular reason to recommend
topical capsaicin instead of topical NSAIDs when all the available
evidence is reviewed [60]. In fact, despite some evidence of
efﬁcacy against placebo, there is increased risk of local adverse
reactions and no comparative trials with topical or oral NSAIDs.Step 2: Advanced pharmacological management in the persistent
symptomatic patients
The task force agreed that patients with mild-to-moderate pain
due to knee OA can be appropriately managed by careful applica-
tion of core set and Step 1 treatment modalities. However, if Step 1
shows inadequate efﬁcacy or in patients arriving to the observa-
tion with moderate-to-severe pain, beneﬁt may be achieved with
advanced pharmacological treatment. However, these treatments
are less manageable and/or prone to more severe adverse
reactions.
In this respect, a central role within the pharmacological
management of OA is traditionally represented by the use of oral
NSAIDs. Recourse to oral NSAIDs may occur early for rescue
analgesia in very short treatment cycles. In fact, oral non-
selective or COX-2-selective NSAIDs provide better symptom relief
than paracetamol [63], with an effect size on pain of 0.29 (0.22–
0.35) [39], which is double the effect of paracetamol [63]. Indeed,
patients show a higher preference for NSAIDs compared to
paracetamol [64]. Although systematic reviews of head-to-
head trials show no clear difference between glucosamine
sulfate and oral NSAIDs for pain or function [60], with better
safety of the former [35], the task force believes that based on
the available clinical trial evidence, NSAIDs may be appropriate
in patients with more severe pain, particularly if the SYSADOA
has failed to effectively control symptoms. On the other hand,
SYSADOAs may decrease NSAID use if adopted as a background
therapy [65].
Oral NSAIDs may be used intermittently or continuously,
although even the latter is not represented by chronic use but by
longer cycles, because of safety concerns and the paucity of long-
term trials. Recent systematic reviews of the many, mostly short-
term, clinical trials show no clear differences in efﬁcacy betweenCOX-2 selective, partially selective, or non-selective NSAIDs [60].
Drug choice within available NSAIDs is therefore dictated by their
safety proﬁle according to the different risk factors and patients'
concomitant diseases and medical conditions.
While COX-2-selective agents are associated with fewer gastro-
intestinal ulcer complications than non-selective NSAIDs over
short-term use, this is not clear over longer periods of treatment
[60], in particular for celecoxib [66] or etoricoxib [67], which are
the only COX-2-selective agents left in the market in Europe.
Indeed, recent evidence suggests that coxibs signiﬁcantly increase
the risk of upper gastrointestinal complications compared
to placebo, although at a lower rate than non-selective NSAIDs
[68]. Thus, on one hand non-selective NSAIDs should always be
co-prescribed with proton pump inhibitors (PPI). However, for
the reasons described above and for recent cost-effectiveness
evidence [69], the task force believes that in patients with normal
gastrointestinal risk, physicians should consider whether a PPI
should be co-prescribed also with COX-2-selective NSAIDs. In
patients with increased gastrointestinal risk, non-selective NSAIDs
should be avoided and COX-2-selective NSAIDs should be co-
prescribed with a PPI [70]. Concomitant use of aspirin increases
non-selective NSAID gastrointestinal risk and at least partially
negates COX-2-selective NSAID improved gastrointestinal toler-
ance [71]: addition of a PPI is beneﬁcial and reduces the risk in
either case [60].
There is little doubt that all NSAIDs, selective and non-selective,
increase the risk of serious cardiovascular events; however,
naproxen is usually associated with lower risk for thrombotic
cardiovascular events [60]. This was conﬁrmed in a recent meta-
analysis of individual patient data from 639 randomized controlled
trials [68], in which coxibs and diclofenac were shown to increase
major vascular events by a third, mainly because of increased
major coronary events (including fatal and non-fatal myocardial
infarction) that occurred also with ibuprofen but not with nap-
roxen that did not increase the general vascular risk, probably due
to its sustained suppression of platelet aggregation [68]. In 2012,
EMA stated that data suggest that naproxen may be associated
with a lower risk for arterial thrombotic events than COX-2
inhibitors and other NSAIDs, although a small risk cannot be
excluded [72]. This latter opinion is shared by the FDA, which
recently decided not to recommend changes in the cardiovascular
warning for naproxen based on the totality of the evidence from
systematic reviews of observational studies and randomized con-
trolled trials (Hochberg MC, personal communication).
While earlier evidence suggested that the relative risk of
cardiovascular events increases with increased baseline cardiovas-
cular risk at the start of treatment with COX-2-selective NSAIDs
[73], the most recent and comprehensive meta-analysis found that
the proportional increase in risk was similar irrespective of base-
line risk [68]; however, the excess absolute risk is in any case
higher in patients at high risk of major cardiovascular events and
receiving coxibs or diclofenac and, probably, ibuprofen [68]. For
this reason, the task force suggests to avoid coxibs and high-dose
diclofenac or ibuprofen in high cardiovascular risk patients. How-
ever, this may apply to other non-selective NSAIDs as well
(naproxen being a possible exception), based on observational
studies [74] where the risk is persistently elevated [75], suggesting
much caution. On the other hand, naproxen, because of its possibly
lower cardiovascular risk [68,75], may be the preferred agent if an
NSAID should be used in patients at high cardiovascular risk.
Concomitant use of low-dose aspirin did not attenuate the
increased cardiovascular risk associated with COX-2-selective
NSAIDs in placebo-controlled trials [76,77], while observational
studies did not ﬁnd increased cardiovascular risk when non-
selective NSAIDs, other than ibuprofen, are added to low-dose
aspirin [60]. Actually, this does not apply to ibuprofen, which has a
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of aspirin and should be therefore avoided [78].
The association of NSAIDs with increased cardiovascular risk is
a complex issue that, besides being directly mediated by prosta-
noid imbalance [79], may have indirect causality linked to the
increase in blood pressure, congestive heart failure, and renal
dysfunction associated with all NSAIDs [80] that should be always
considered by physicians. In particular, it may be useful to suggest
avoiding oral NSAID use in patients with increased renal risk, such
as chronic kidney disease with estimated glomerular ﬁltration rate
below 30 cc/min [4].
In case of contraindications to NSAIDs, or if the patient is still
symptomatic despite use of NSAIDs or was severely symptomatic,
intra-articular treatment may be applied.
The role of intra-articular hyaluronic acid injections has been
controversial, but most meta-analyses have shown a signiﬁcant
beneﬁt in knee osteoarthritis, which is small when restricted to
high-quality trials [7]. However, a more recent meta-analysis showed
an effect size of 0.34 (0.22–0.46), which is hindered by high
heterogeneity but survives several sensitivity analyses based on trial
quality and, importantly, the small effects last up to 6 months after
treatment [81]. These favorable results are conﬁrmed by another
recent meta-analysis in which, on the other hand, the authors make
negative conclusions based on selective, and questionable, evidence
[82] and that this task force does not endorse. Indeed, intra-articular
hyaluronic acid injections are relatively safe, although pseudoseptic
reactions have been reported especially with cross-linked formula-
tions of the highest molecular weight. In addition, hyaluronic acid
induces longer-lasting pain control compared with intra-articular
corticosteroids [83] and may delay total joint replacement [84]. In
addition, recent ﬁndings suggest that there are no signiﬁcant differ-
ences in symptom efﬁcacy compared with oral NSAIDs [85]; indeed,
intra-articular hyaluronic acid might be a good alternative to NSAIDs
in knee OA in older patients or in those at greater risk for NSAID-
induced adverse effects.
Intra-articular corticosteroids may be suggested in patients
especially when there is an effusion, although this recommenda-
tion is more theoretical than based on actual evidence. Practically,
joint aspiration of the synovial ﬂuid is directly followed by
intra-articular administration of corticosteroids, e.g., methylpred-
nisolone acetate or triamcinolone hexacetonide. They indeed
have higher efﬁcacy than intra-articular hyaluronic acid over
the ﬁrst weeks after administration [83], but their effect on
pain may actually last for only a few (1–3) weeks in controlled
trials [86]. Safety is good, with some evidence also over repeated
cycles [87] if scheduled because of the short-lasting analgesic
effect.
Step 3: Last pharmacological attempts before surgery
A patient who has failed all the above sequential approaches
may be considered as a candidate to surgery. Last pharmacological
chances for the severely symptomatic patient may be represented
by the recourse to short-term weak opioids. The efﬁcacy of
tramadol in relieving pain and improving function in knee osteo-
arthritis is small but signiﬁcant [88]; adverse events are signiﬁ-
cantly increased over placebo and (although they may be mostly
minor) they may lead to treatment withdrawal in a substantial
proportion of patients [88]. In general, opioids used in arthritis
patients are associated with signiﬁcant morbidity and should be
used with extreme caution [89]. Combination therapy with tra-
madol and paracetamol has been shown to be effective when
added to NSAIDs in patients who have not adequately responded
to the latter [90]. However, the safety issues seem to be the same
for tramadol alone and it is unclear whether combining only
paracetamol with NSAIDs in these patients would also result in
improved efﬁcacy but less adverse effects [91].Antidepressants are commonly used in chronic pain syndromes
because they alter pain neurotransmitters (i.e., serotonin and
norepinephrine) centrally, which may to some extent be applicable
also to tramadol. Indeed, central sensitization may play a role in
the severity of osteoarthritis pain [92]. In this respect, evidence for
the use of duloxetine in knee osteoarthritis derives mainly from
two randomized, placebo-controlled trials of short-term, 13 weeks,
duration showing beneﬁt in clinically relevant outcomes but a
similar likelihood to elicit adverse reactions, such as nausea,
fatigue, constipation, dry mouth, and others [93]. In a similarly
short-term study, duloxetine improved knee pain in patients with
an inadequate response to NSAIDs [94], which would conﬁrm the
drug's possible role in advanced patient management. Additional
and longer term evidence is needed before moving duloxetine to
earlier steps in the management of the disease. Actually, early
physical examination may allow recognition of patients with
central sensitization [95] who thus may beneﬁt from central
analgesics earlier in the course of the disease management.
Step 4: End-stage disease management and surgery
Full review and advice on surgical procedures for the manage-
ment of end-stage knee OA goes beyond the scope of the task
force's commitment. However, there is little doubt that total joint
replacement is cost-effective when all previous modalities have
failed and there is signiﬁcant loss in quality of life, although this is
based mainly on studies other than randomized controlled trials
[96] for obvious reasons. Total joint replacement is very effective in
relieving severe symptoms of knee OA and has a high beneﬁt/risk
ratio when patients are carefully selected, well informed, anes-
thesia and surgery are well performed, and rehabilitation is
appropriate [10]. The latter is particularly important when started
immediately after surgery and normal activities can be then
resumed 6–12 weeks after the intervention, with 95% of all joint
replacement prostheses expected to survive into the second
decade after surgery; only around 20% of patients do not beneﬁt
following total joint replacement [10].
Unicompartmental knee replacement is effective when the
disease is restricted to a single knee joint compartment and
patients may experience fewer complications such as deep vein
thrombosis [97]. Among other surgical procedures, there is some
evidence for certain efﬁcacy of high tibial osteotomy for medial
compartment knee disease [98] and no favorable evidence for joint
lavage/debridement [99].
For severely symptomatic patients in whom surgery is contra-
indicated or if they are unwilling to undergo surgery, the last
pharmacological chance may be represented by classical oral or
transdermal opioids, although their small to moderate efﬁcacy is
outweighed by the large increase in the risk of adverse events
[100]. The guidelines for the use of opioid analgesics in the
management of chronic non-cancer pain should be followed [101].Discussion
Among the many current recommendations and guidelines
issued by respectful scientiﬁc societies worldwide for the manage-
ment of osteoarthritis [3–10], this is the ﬁrst effort to produce a
detailed algorithm that guides the physicians through the different
steps of treatment of an individual patient.
The only previous attempt to generate an algorithm was
performed with the NICE guidelines [9,10]. However, this is limited
by regulatory approvals in UK (not all drugs taken into consid-
eration here have the same regulatory history in UK than in other
European countries) and, especially, by considerations on sustain-
ability by the UK National Health System (NHS). Indeed, there are a
limited number of pharmacological options considered in the ﬁnal
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the particular shape of the NICE algorithm) after the core inter-
ventions (education, exercise, and weight loss) with low, if any,
degree of prioritization in the third and most comprehensive step
that spans from oral NSAIDs to joint arthroplasty. These limitations
did not improve with the new NICE guideline update [10].
Other recently released recommendations, such as the Ameri-
can College of Rheumatology guidelines [4], as it may be the case
in other countries, are also inﬂuenced by the incomplete local
availability of all drugs considered in our present effort. In
addition, the ACR panel deliberately decided not to develop an
algorithm but to use a formal process to rate the available
evidence. Such process led to the absence of what the process
designated as “strong recommendation” for any pharmacological
interventions for knee OA, except for oral NSAIDs in patients with
an inadequate response to acetaminophen (paracetamol) and do
not have contraindications to these agents. Almost all pharmaco-
logical treatments were rated with a “conditional (weak) recom-
mendation” and some received “no recommendation.” The ACR
guidelines' authors acknowledged that while most of the recom-
mendations will not be controversial, some may be met with
disagreement [4].
Similar limitations are applicable to the new OARSI guidelines.
OARSI has a strong tradition of detailed evidence-based analysis
with clear recommendations on the use of a given intervention [5–7].
In the latest guidelines [8], OARSI has chosen a “minimalist”
approach in which the evidence is only brieﬂy, and often incom-
pletely, substantiated, and interventions are put in a mere alpha-
betical order, with the majority of them being classiﬁed with an
“uncertain” recommendation. Only a small proportion of them
received an “appropriate” recommendation, and knee OA patients
with co-morbidities (the vast majority within this elderly patient
population) are left only with topical NSAIDs and intra-articular
corticosteroids as recommended appropriate treatments, beside
the possible use of biomechanical interventions and a walking cane
[8]. Therefore, the ESCEO task force found not particularly compel-
ling the differentiation between an “appropriate” and an “uncer-
tain” recommendation, the latter being difﬁcult to interpret for the
prescribing physician.
The algorithm proposed here summarizes the evidence on all
proposed treatments and puts them in the sequence suggested by
the evidence itself. Although one major limitation consists in the
lack, in the vast majority of cases, of appropriate clinical studies on
treatment prioritization, it is the ﬁrm opinion of the task force that
the evidence from available standard trials is sufﬁcient to propose
a given intervention at a certain step of the algorithm.
Following the core set that, in agreement with most existing
recommendations and guidelines, includes information/education,
weight loss if the patient is overweight, and the establishment of
an appropriate exercise program, the algorithm proposes four
multimodal steps. During Step 1, there is an attempt to better
characterize the use of paracetamol as the initial pharmacological
intervention. Given its limited efﬁcacy and some recent concerns
on its safety, the task force proposes that paracetamol may remain
for rescue analgesia during a background treatment with SYSA-
DOAs, such as glucosamine sulfate or chondroitin sulfate: both of
the latter should be not only of pharmaceutical grade, but speciﬁc
prescription drugs are approved in Europe and elsewhere and they
are the only products the task force recommends on the basis of
the strong clinical evidence, including safety and the possibility of
additional beneﬁt when used in the early steps of disease manage-
ment [36,37,46].
Topical NSAIDs may be added for additional analgesia given
their short-term symptomatic efﬁcacy similar to that of their oral
counterparts and good systemic safety. Moreover, during this ﬁrst
step, appropriate background non-pharmacological treatmentshould be established beyond the core set and added sequentially
at any time throughout prosecution of the algorithm ﬂow, accord-
ing to patient's response.
Step 2 consists of the advanced pharmacological management in
the persistently symptomatic patient. It is acknowledged here that
the central role within this step is represented by the recourse to oral
NSAIDs. Despite the unclear differentiation in the available direct
comparisons between oral NSAIDs and SYSADOAs or topical NSAIDs,
the task force believes that the former may be more effective in more
severe patients. On the other hand, the most important safety
considerations were reviewed here and brought to the recommen-
dation that oral NSAIDs should not be used chronically, but inter-
mittently or continuously in longer treatment cycles. Secondly, such
safety considerations led to different selection principles among non-
selective or COX-2-selective NSAIDS, depending on the underlying
gastrointestinal, cardiovascular, or renal risk.
Intra-articular treatment represents a more advanced pharma-
cological measure. Indeed, both hyaluronic acid and corticoste-
roids have mainly been studied in patients who have failed prior
analgesic or anti-inﬂammatory treatment. Both the treatments can
be clinically differentiated by the duration of the induced beneﬁt,
which is stronger for intra-articular corticosteroids but short-lived
(a few weeks following a single injection) compared to hyaluro-
nate whose effect size is smaller (and more controversial) but
lasting for up to 6 months after a 1–3 weekly treatment course.
Step 3 consists of the last pharmacological attempt before
surgery and includes oral weak opioids or duloxetine, whose still
partial evidence was obtained in non-responders to previous
treatment; the mild efﬁcacy is challenged by adverse reactions
that may lead to frequent patient withdrawal and signiﬁcant
morbidity [89].
Finally, end-stage disease management is the last or fourth step
within the algorithm and consists of surgical procedures mainly
represented by total joint replacement, with classical opioids as a
difﬁcult-to-manage alternative for patients in whom surgery is
contraindicated.
Importantly, the algorithm developed here is to our knowledge
the ﬁrst attempt to provide guidance on combination or multi-
modal therapy. In fact, ﬁrst of all, the task force believes that the
core set given here should always be enforced in all patients,
similar to the background treatment foreseen in Step 1, which
already provides advice for multimodal therapy by suggesting on
one side addition at any time of non-pharmacological treatment
modalities when needed and, on the other side, the addition of
topical NSAIDs to chronic SYSADOAs (with paracetamol for rescue
analgesia) for further pain control if appropriate. When patients
are moved to Step 2 and thus to treatment with oral NSAIDs, the
background treatment of Step 1 should not be withdrawn since it
can still provide a different approach to disease and limit the use
of NSAIDs. Similarly, the decision to start intra-articular hyaluro-
nate or corticosteroids if the patient is still symptomatic should
not lead automatically to abandon any of the previous treatment
modalities. Things get more complicated when the patient enters
Step 3 because of insufﬁcient symptom control; it may be safe to
say that while Step 1 modalities might continue because they may
provide different long-term beneﬁt, the extent to which treat-
ments adopted in Step 2 should be replaced depends on the overall
beneﬁt/risk ratio. Obviously, Step 4 changes all the perspective,
especially when it involves deﬁnitive surgical procedures.
The present effort is an expert consensus strongly based on the
available evidence. Among scientiﬁc societies within the Rheuma-
tology area, ESCEO is the only one devoted to two speciﬁc
disorders, such as osteoporosis and osteoarthritis, given the many
biological connections between the bone and the joint. While most
experts in the present task force have actually clinical and research
expertise in both diseases or predominantly in OA and have widely
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research interest in osteoporosis. However, all of them are physi-
cians specialized within rheumatological areas, have a huge
expertise in the care of patients with OA, and sit on scientiﬁc
boards devoted to OA and pharmacoeconomics of rheumatic
disorders.
When looking at all treatment modalities considered, the task
force believes that a complete overview has been provided for
non-pharmacological background treatment while, as mentioned,
a more extensive review of surgical procedures in Step 4 would
have gone beyond the scopes of these recommendations. Con-
versely, virtually all pharmacological treatments available have
been reviewed and included in the algorithm, with the relevant
comments. Drug classes that have not been reviewed here include
bisphosphonates, due to failure of the phase III clinical trials with
risedronate in controlling symptoms and joint structure disease
progression, despite favorable changes in some biomarkers [102].
Muscle relaxants have not been included as well, due to the lack of
appropriate trials in osteoarthritis, while studies have concen-
trated in other rheumatological conditions (e.g., cyclobenzaprine
in ﬁbromyalgia).
As any guidance document the present effort suffers from the
limitations imposed by the generation of new evidence that may
accumulate in the meantime and will need periodic revisions. For
the time being, it contains easy-to-follow and evidence-based
advice on how and when establishing a treatment ﬂow in patients
with knee OA. In addition, this document represents the attempt
for a new framework for the development of new international
guidelines for the management of OA that is more easily accessible
and understandable to specialists and practicing physicians.References
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